Unknown

Dataset Information

0

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.


ABSTRACT:

Purpose

Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors.

Materials and methods

By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above.

Results

Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm3; EBV DNA 0 copy/mL, GTVtotal ≥ 30 cm3; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm3) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal ≥ 30 cm3). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant.

Conclusion

Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.

SUBMITTER: Chen QY 

PROVIDER: S-EPMC6056955 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.

Chen Qiu-Yan QY   Guo Shao-Yan SY   Tang Lin-Quan LQ   Lu Tong-Yu TY   Chen Bo-Lin BL   Zhong Qi-Yu QY   Zou Meng-Sha MS   Tang Qing-Nan QN   Chen Wen-Hui WH   Guo Shan-Shan SS   Liu Li-Ting LT   Li Yang Y   Guo Ling L   Mo Hao-Yuan HY   Sun Rui R   Luo Dong-Hua DH   Zhao Chong C   Cao Ka-Jia KJ   Qian Chao-Nan CN   Guo Xiang X   Zeng Mu-Sheng MS   Mai Hai-Qiang HQ  

Cancer research and treatment 20170913 3


<h4>Purpose</h4>Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors.<h4>Materials and methods</h4>By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the  ...[more]

Similar Datasets

| S-EPMC4868751 | biostudies-literature
| S-EPMC7136458 | biostudies-literature
| S-EPMC6055246 | biostudies-literature
| S-EPMC6763945 | biostudies-literature
| S-EPMC4642560 | biostudies-other
| S-EPMC5858492 | biostudies-literature
| S-EPMC7020924 | biostudies-literature
| S-EPMC4770420 | biostudies-literature
| S-EPMC4416016 | biostudies-literature
| S-EPMC6219576 | biostudies-literature